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doi:10.1016/j.jtcvs.2003.11.034Background: Reactive oxygen-derived species, including those generated during
myocardial ischemia and reperfusion induced by cardioplegia, have been suggested
to be involved in myocardial apoptosis induction. The purpose of our study was to
investigate (1) whether cardioplegic arrest initiates apoptosis in the hearts of cardiac
surgery patients and (2) whether reactive oxygen-derived species scavenging with
N-acetylcysteine attenuates myocardial apoptosis initiation.
Methods: In transmural left ventricular biopsy samples collected before and at the
end of cardiopulmonary bypass, we densitometrically determined cardiac myocyte
staining intensity for active caspases-3 and -7, the apoptosis signal pathway central
effector enzymes. The left ventricular biopsy samples had been obtained from 36
coronary artery bypass graft patients randomized in a double-blind fashion to
receive either N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime
followed by infusion at 20 mg · kg1 · h1; n  18) or placebo (n  18).
Results: The change in left ventricular cardiac myocyte staining (end of cardiopul-
monary bypass minus before cardiopulmonary bypass) differed significantly be-
tween groups for both measures: caspase-3, 3.1  4.5 gray units (mean  SD;
N-acetylcysteine group) versus 7.1  8.1 gray units (placebo); 95% confidence
interval, 6.4 to 14.4; P .0001; caspase-7,5.1 6.1 gray units (N-acetylcysteine)
versus 5.1  5.7 gray units (placebo); 95% confidence interval, 6.3 to 15.0; P 
.0001. Clinical outcome did not differ between N-acetylcysteine and placebo.
Conclusions: Our data show that cardioplegic arrest initiates the apoptosis signal
cascade in human left ventricular cardiac myocytes. This apoptosis induction can
effectively be prevented by N-acetylcysteine.
Apoptosis has been shown to be involved in various cardiac pa-thologies, including heart failure, cardiomyopathy, myocarditis,and myocardial ischemia/reperfusion.1-3 Apoptosis can be trig-gered through different mechanisms in response to both intracel-lular and extracellular signals.4,5 For example, cytokine release bymacrophages and myocytes can activate the apoptosis signal
cascade.6 In addition, reactive oxygen-derived species (ROS), often called oxidative
stress, have been shown to induce apoptosis in cardiac myocytes subjected to
ischemia and reperfusion.7,8 Accordingly, we and other researchers have recently
demonstrated that cardioplegia-induced ischemia and reperfusion is associated with
apoptosis initiation in adult porcine,9 canine,10 and rat11 and neonatal lamb left
ventricular (LV) myocytes,12 as well as human atrial myocytes.13 Because cardiac
apoptosis has been suggested to be involved in postoperative myocardial stunning,13
cardiac apoptosis prevention could represent an attractive adjunct to current myo-
cardial protection techniques in cardiac surgery.
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ROS scavenging. Experimentally, Dobsak and colleagues11
have recently shown that ROS scavenging with the iron
chelator deferoxamine resulted in fewer apoptotic myocytes
associated with better functional recovery in rat hearts after
4 hours of cardioplegic arrest. We have recently demon-
strated that the antioxidant and ROS scavenger N-acetyl-
cysteine (NAC) prevented direct ROS-mediated myocardial
alterations in the LV myocardium of patients subjected to
cardioplegia14; however, whether NAC attenuates cardiac
apoptosis initiation has not been investigated.
Therefore, the purpose of our study was to compare the
effects of NAC versus placebo on activation of caspases-3
and -7, the apoptosis signal pathway central effector en-
zymes, in LV myocardium of patients subjected to coronary
artery operation during cardioplegic arrest.
Materials and Methods
After approval by the University of Cologne Human Ethics Com-
mittee, written, informed consent was obtained from each patient
during the preoperative interview. We used LV biopsy specimens
14
TABLE 1. Baseline demographic and clinical characteris-
tics of trial groups14
Characteristic
NAC group
(n  20)
Placebo group
(n  20)
Age, y (mean  SD) 66.2 11.8 66.5 6.5
Female, n (%) 8 (40) 1 (5)
Arterial hypertension,
n (%)
17 (85) 16 (80)
Diabetes, n (%) 7 (35) 6 (30)
Smoking history, n (%) 9 (45) 7 (35)
Previous myocardial
infarction, n (%)
6 (30) 10 (50)
Vessel disease, n (%)
1 1 (5) 0 (0)
2 3 (15) 4 (20)
3 16 (80) 16 (80)
Body mass index, kg/
m2 (mean  SD)
27.3 4.4 27.8 3.7
Angiographic LV
ejection fraction, %
(mean  SD)
57.9 16.7 (n 17)* 63.9 14.1 (n 17)*
LVEDP, mm Hg (mean
 SD)
15.5 8.3 (n 15)* 14.8 6.7 (n 13)*
Cardiac index, L ·
min1 · L2 (mean
 SD)
2.47 0.45 (n 19)† 2.55 0.47
FAC, % (mean  SD) 63.1 11.0 (n 18)‡ 61.0 11.3 (n 17)‡
NAC, N-Acetylcysteine; LVEDP, left ventricular end-diastolic pressure;
FAC, fractional area of contraction as determined by transesophageal
echocardiography before cardiopulmonary bypass.
Reasons for missing values (n  20) are *not determined at the time of
heart catheter insertion; †catheter placement impossible; and ‡trans-
esophageal echocardiography not performed.from our previous study, in which we randomized 40 patients (9
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artery bypass surgery into either the NAC group (n  20) or the
placebo group (n  20) according to a computer-generated allo-
cation list. Patients’ biometric data and procedures are given in
Tables 1 and 2 according to reference.14 Briefly, patients of the
NAC group received 100 mg of NAC per kilogram body weight
into the cardiopulmonary bypass (CPB) prime followed by intra-
venous infusion at 20 mg of NAC per kilogram of body weight per
hour until the end of CPB; patients in the placebo group received
equivalent amounts of placebo. Patients were subjected to CPB at
32°C to 34°C, the aorta was crossclamped, and myocardial revas-
cularization was performed during cardioplegic arrest by using
single-shot antegrade cold (4°C) crystalloid Bretschneider cardio-
plegia (Custodiol; Dr Ko¨hler Chemie, Alsbach, Germany).
LV Biopsies
Before CPB initiation, we collected a transmural biopsy sample
from a fat-free area of the LV anterior wall by using a 14-gauge
biopsy needle (Gallini, Modena, Italy). A second LV biopsy sam-
ple was taken at the end of the extracorporeal circulation before
weaning from CPB. All LV biopsy samples were placed in 4%
paraformaldehyde for 4 hours and then rinsed in 0.1 mol/L phos-
phate-buffered saline (PBS) for 24 hours, followed by storage for
12 hours in PBS solution with 18% sucrose for cryoprotection.
Finally, they were frozen at 80°C. Because of the small size of
the LV biopsy samples, we were able to densitometrically quan-
titate cardiac myocyte staining for active caspase-3 (before CPB
and at the end of CPB) in 18 patients of the placebo group and 18
patients of the NAC group and for active caspase-7 in 17 patients
of the placebo group and 17 patients of the NAC group.
Immunocytochemistry
Before immunohistochemical examination, 7-m slices from the
biopsy samples were placed in a bathing solution of 3% H2O2 and
methanol for 20 minutes, and then cells were lysed with 0.25%
Triton X-100 (Rohm & Haas Co, Philadelphia, Pa) in ammonium
chloride 0.5 mol/L. Thereafter, specimens were treated with 5%
bovine serum albumin solution in Tris-buffered saline (TBS) 0.05
mol/L. Before each step, the sections were rinsed 3 times in TBS
buffer 0.05 mol/L. Incubation with primary rabbit anti–active
caspase-3 antibody (1:500; Pharmingen, San Diego, Calif) and
rabbit anti–active caspase-7 antibody (1:500; Biocat, Heidelberg,
Germany) were performed in a TBS-based solution of 0.8% bovine
serum albumin and NaN3 20 mmol/L for 12 hours at 4°C. After
rinsing with TBS, the sections were incubated with the correspond-
ing secondary biotinylated goat anti-rabbit antibody (1:400;
DAKO, Hamburg, Germany) for 1 hour at room temperature. A
streptavidin-horseradish-peroxidase complex was then applied as a
detection system (1:150) for 1 hour. Finally, staining was devel-
oped for 10 to 20 minutes with 3,3-diaminobenzidine tetrahydro-
chloride in PBS 0.1 mol/L.
Active Caspase-3 and Caspase-7 Television Densitometry
All LV biopsy slices were incubated and stored under identical
conditions. For quantitative intensity analyses of active caspase-3
and -7 immunostaining in cardiac myocytes, we measured the gray
values of 30 cardiac myocytes from 6 randomly selected areas. The
staining intensity was reported as the mean measured cardiac
2004
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Pmyocyte gray value minus the background gray value. The back-
ground gray value was measured at a cell-free area of the slice. For
staining intensity detection, a Zeiss (Jena, Germany) Axiophot
microscope coupled to a 3-chip charge-coupled device camera was
used, and analysis was performed by using the Optimas 6.01
image-analysis program (Optimas 6.01, Media Cybernetics, Silver
Spring, Md) installed on a personal computer.
Statistical Analysis
Continuous variables were summarized as mean SD. Changes in
outcome variables were analyzed for statistical significance at a
level of   5% by using 2-tailed Student t tests for unpaired or
paired samples, where appropriate. Corresponding 95% confidence
intervals (CI) are given to allow assessment of effect sizes for
clinical relevance. Statistical analyses were performed with the
software package SPSS for Windows, release 10.0.7 (SPSS Inc,
Chicago, Ill). The P values reported were not adjusted for multiple
testing.
Results
Cardiac myocyte immunostaining for active caspases-3 and
-7 is depicted in Figure 1. Compared with before CPB, LV
cardiac myocytes of the placebo group demonstrated
TABLE 2. Perioperative characteristics and post– cardiopu
Characteristic
Grafts, n (%)
1
2
3
4
5
ITA use, n (%)
Hospital mortality, n (%)
Perioperative myocardial infarction, n (%)
Duration, min (mean  SD)
Operation
Cardiopulmonary bypass
Aortic crossclamp
Reperfusion
Dopamine, g · kg1 · min1 (mean  SD)
Postoperative CK, U/L (mean  SD)
Postoperative CK-MB, U/L (mean  SD)
Heart rate, beats/min (mean  SD)
Arterial blood pressure, mm Hg (mean  SD)
PAP, mm Hg (mean  SD)
PCWP, mm Hg (mean  SD)
CVP, mm Hg (mean  SD)
SVRI, dyne  s1  m2  cm5 (mean  SD)
PVRI, dyne  s1  m2  cm5 (mean  SD)
ITA, Internal thoracic artery; PAP, pulmonary artery pressure; PCWP, pulm
vascular resistance index; PVRI, pulmonary vascular resistance index; CK
teine.
Reasons for missing values (n  20) are *data not in patient chart; †no p
balloon; §calculation not possible because of ‡ (n  1) and n  1 was ecaspase-3 and -7 activation at the end of CPB. In contrast,
The Journal of Thoracicardiac myocytes of the NAC group remained negative for
both caspases at the end of CPB. In the placebo group,
caspase-3 staining increased from 11.6  2.4 gray units
before CPB to 18.7  8.0 gray units at the end of CPB (P
 .0017; 95% CI for mean change, 3.4 to 10.9), and
caspase-7 staining increased from 23.8  11.2 gray units
before CPB to 28.9  12.0 gray units at the end of CPB (P
 .0019; 95% CI for mean change, 2.4 to 7.8). In the NAC
group, caspase-3 staining decreased from 14.9  3.4 gray
units before CPB to 11.7  2.6 gray units at end of CPB (P
 .009; 95% CI for mean change, 1.1 to 5.2), and
caspase-7 staining decreased from 25.8  11.0 gray units
before CPB to 20.8  11.3 gray units at the end of CPB (P
 .003; 95% CI for mean change, 2.2 to 8.0). The
changes (from before CPB to the end of CPB) in cardiac
myocyte density for caspases-3 and -7 are depicted in Fig-
ure 2.
Patients’ biometrics, intraoperative procedures, and clin-
ical outcomes were similar between groups; there were no
deaths or perioperative myocardial infarctions14 (Tables 1
and 2). We did not observe adverse effects attributable to
ary bypass hemodynamics of trial groups14
NAC group
(n  20)
Placebo group
(n  20)
1 (5) 0 (0)
1 (5) 5 (25)
10 (50) 9 (45)
7 (35) 5 (25)
1 (5) 1 (5)
20 (100) 18 (90)
0 (0) 0 (0)
0 (0) 0 (0)
175 25 157 20
80 19 73 18
43 10 38 9
28 7 27 8
4.2 1.6 4.2 1.4
84.8 26.3 86.6 23.3 (n 19)*
13.0 3.7 10.3 3.9 (n 19)*
91.2 10.7 88.5 12.9
69.0 8.5 70.0 9.2
15.7 5.8 (n 19)† 14.1 4.0
9.8 5.3 (n 19)† 9.7 3.9 (n 19)‡
7.8 3.9 (n 19)† 7.0 4.3
516 471 (n 19)† 1325 256
143 75 (n 19)† 110 49 (n 18)§
capillary wedge pressure; CVP, central venous pressure; SVRI, systemic
tine kinase; CK-MB, creatine kinase myocardial band; NAC, N-acetylcys-
ary artery catheter; ‡no wedge position of the pulmonary artery catheter
ed because of a negative value (PAP  PCWP).lmon
1
onary
, crea
ulmon
xcludNAC. Post-CPB hemodynamics, including heart rate, vas-
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CSPcular pressures, systemic and pulmonary vascular resis-
tance, cardiac index, LV function as measured by trans-
esophageal echocardiography, and positive inotropic
medication, were similar between groups14 (Tables 1 and 2).
We did not find differences among the degree of caspase
staining and arterial hypertension, diabetes mellitus, LV
Figure 1. Immunostaining for active caspases-3 and -7
with before CPB (a and e), LV cardiac myocytes of the
(f) activation at the end of CPB. In contrast, cardiac myo
(c and g), were negative for both active caspase-3 (d)ejection fraction, or LV end-diastolic pressure (P  .27).
106 The Journal of Thoracic and Cardiovascular Surgery ● JulyDiscussion
Our data show that NAC prevents cardioplegia-induced
apoptosis signal cascade initiation in human LV myocar-
dium, because both cardiac myocyte caspase-3 and
caspase-7 activities were significantly lower in patients who
received NAC compared with placebo. Together with our
ardiac myocytes and capillaries shows that compared
ebo group demonstrated caspase-3 (b) and caspase-7
s of the NAC group, even if slightly stained before CPB
ctive caspase-7 (h) at the end of CPB (bar  35 m).in c
plac
cyteclinical trial, which demonstrated that NAC protected the
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Pmyocardium from direct ROS-mediated alterations such as
8-iso-prostaglandin-F2 and nitrotyrosine formation,14
these data show for the first time that ROS scavenging can
effectively attenuate cardiac myocyte apoptosis induction in
patients who undergo cardioplegia.
Apoptosis is a genetically programmed process for the
death and subsequent removal of injured cells. Several
extracellular and intracellular stimuli, including cytokine
release, mechanical stretch, and oxidative stress, can trigger
the apoptosis signal cascade.4-6 The apoptosis execution
phase is initiated by cleavage and, thus, activation of down-
stream or effector caspases such as caspases-3 and -7.4,5
Subsequently, these activated caspases can cleave genomic
DNA, leading to DNA fragmentation and, ultimately, apo-
ptotic cell death.4,5 Even though the clinical relevance of
cardioplegia-induced apoptosis is not yet well established,
recent work suggests that apoptosis is initiated by cardiople-
gic arrest in diseased adult hearts and may contribute to
postoperative myocardial stunning.13 It has to be noted,
however, that detection of cleaved caspases as performed in
this study does not necessarily indicate substrate cleavage
by activated caspases, because inhibitory proteins may
block cleaved caspases. In fact, this inhibition of the apo-
ptosis signal cascade explains the unchanged post-CPB
cardiac function without signs of massive apoptotic cardiac
cell loss despite the homogeneous myocardial apoptosis
initiation induced by cardioplegia and reperfusion. How-
ever, considering the potential long-term effects attributable
to apoptosis initiation, including mitochondrial alterations,
functional and structural protein derangement, and acceler-
ated cell aging,4,5,15 apoptosis prevention has to be regarded
as a cardioprotective measure.
Because ROS can trigger apoptosis4,5,7-9 and because
cardioplegia-induced myocardial ischemia/reperfusion is
associated with massive ROS production,16 ROS scaveng-
ing may attenuate apoptosis induction in hearts exposed to
cardioplegia. Experimentally, effective apoptosis preven-
tion by ROS scavenging with the glutathione peroxidase
mimic ebselen has been demonstrated in a clinically rele-
vant pig model of regional myocardial ischemia and car-
dioplegic arrest.17 In addition, ROS scavenging with the
iron chelator deferoxamine resulted in fewer apoptotic myo-
cytes and better functional recovery in rat hearts after 4
hours of cardioplegic arrest.11 In this study, we found that
the antioxidant and reduced glutathione precursor NAC
prevented the activation of caspases-3 and -7 in the LV
myocytes of patients subjected to cardioplegia. In contrast,
the hearts of patients in the placebo group demonstrated
significant caspase-3 and -7 activation, indicating apoptosis
signal cascade initiation. Although the early postoperative
hemodynamics and short-term clinical outcome were not
14different between the NAC and placebo groups, these data
The Journal of Thoracisuggest that ROS scavenging with NAC may be a useful
adjunct to myocardial protection strategies.
It is interesting that we found that in the NAC group,
cardiac myocyte caspase-3 and -7 activities actually de-
creased from before CPB to the end of CPB, indicating
apoptosis signal cascade activation during the period of
anesthesia induction, thoracotomy, and cannulation for
CPB. Because previous work showed myocardial 8-iso-
prostaglandin-F2 and nitrotyrosine formation before
CPB,16 some ROS must have been induced by anesthesia
induction, surgical trauma, or a combination thereof. Thus,
to yield the full potential benefit of its ROS-scavenging
properties, NAC application should start before anesthesia
induction.
In conclusion, our data show for the first time that
cardioplegia-induced apoptosis signal cascade activation in
human LV cardiac myocytes can effectively be prevented
by ROS scavenging with NAC. However, the data of our
study do not allow us to determine how many cardiac
myocytes, if any, completed the apoptosis signal cascade in
hearts not protected by NAC, because apoptosis completion
probably requires several hours18 and, thus, cannot be de-
tected within the time frame of routine coronary artery
surgery. Despite this lack of evidence for apoptosis com-
pletion, caspase activity may still have a significant effect
on myocardial function. As shown by Ricci and col-
leagues,19 caspase-3 cleavage is also associated with func-
tional deficits of complex I and complex II in the electron
transport chain when the outer mitochondrial membrane has
been permeabilized, as occurs upstream of caspase activa-
tion. Therefore, caspase activation inhibition seems to be
beneficial even before apoptosis is completed. Future stud-
Figure 2. Change from before CPB to the end of CPB in cardiac
myocyte density for active caspases-3 and -7 in both groups (data
are mean  SD; for caspase-3, n  18 in the placebo group; n 
18 in the N-acetylcysteine group; for caspase-7, n  17 in the
placebo group; n  17 in the N-acetylcysteine group).ies are required to further elucidate the clinical relevance of
c and Cardiovascular Surgery ● Volume 128, Number 1 107
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tion, and the time course of apoptosis completion.
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